Article
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.
Cancer medicine - 1 Jan 2026
Lin Douglas I, Lawrence Elizabeth, Danziger Natalie, Ye Huihui, Decker Brennan, Gjoerup Ole, Graf Ryon P, Ross Jeffrey S, Huang Richard S P, Elvin Julia A, Mata Douglas A, McKay Rana R
Abstract excerpt
BACKGROUND: Inactivating BRCA1/2 mutations confer sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) in prostate cancer (PCA). However, secondary BRCA1/2 reversion mutations (BRCArev) can restore BRCA function and mediate acquired PARPi resistance. While BRCArev typically arise under PARPi selective pressure, their occurrence in PARPi-naïve settings remains incompletely understood. We sought to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.